Clinical predictors of SARS-CoV-2 vaccine immunogenicity in kidney transplant recipients at a rural center

Table 2 Multivariate logistic regression analysis of factors associated with antibody response

Variable	Odds ratio	Standard error	95%CI	P value
Age (per year increase)	0.95	0.028	0.90-1.01	0.101
Gender (male vs female)	0.75	0.44	0.24-2.39	0.631
Race
Caucasian vs other	23.88	47.14	0.50-1143.83	0.108
Black vs other	43.08	82.52	1.01-1839.96	0.049
BMI	0.99	0.049	0.89-1.09	0.767
eGFR	1.05	0.018	1.02-1.09	0.002
Tacrolimus level	0.93	0.14	0.70-1.24	0.637
MPA dose (mg/day)	0.99	0.002	0.99-1.00	0.01
Basiliximab induction (yes vs no)	31.3	49.1	1.45-677.30	0.028
Thymoglobulin Induction (yes vs no)	16.44	25	0.83-323.82	0.066
Days from transplant to vaccine	1	0.0003	1.00-1.00	0.082
Days from 2nd vaccine to sample testing	1.01	0.0035	1.00-1.01	0.055
Diabetes mellitus	1.39	0.8	0.47-4.13	0.564
Hypertension	1.71	0.94	0.61-4.79	0.307
Vaccine type
Moderna vs other	0.78	0.46	0.28-2.18	0.639
Pfizer vs other	0.57	0.34	0.20-1.66	0.307
SPK or kidney alone	1.03	0.62	0.31-3.42	0.956
History of rituximab use	0.99	0.8	0.20-4.93	0.993
Type of donor (living vs deceased)	1.62	0.92	0.55-4.78	0.38
Previous transplant (yes vs no)	0.82	0.58	0.24-2.75	0.747
Primary ESRD etiology	1.41	0.36	0.90-2.19	0.135
Constant	0.01	0.02	0.00-60.94	0.263

Reference categories for regression models were female sex, other race, absence of induction therapy, absence of calcineurin inhibitor, absence of antimetabolite therapy, absence of steroid therapy, receipt of non-mRNA vaccine, deceased donor transplantation, and absence of the listed comorbidities, unless otherwise specified. BMI: Body mass index; eGFR: Estimated glomerular filtration rate; MPA: Mycophenolic acid; SPK: Simultaneous pancreas kidney; ESRD: End stage renal disease; 95%CI: 95% confidence interval.